Hello tom136-ga,
The results of the research for this question overlap some of the
findings for your other question on Bioadhesive technologies. Both
questions relate to the larger field of drug delivery so some of the
resources I listed for industry and market evaluation are applicable
to both drug delivery methods.
The fast dissolving tablet market is particularly applicable to
children and the elderly and anyone else who has trouble swallowing
regular tablets. The thrust of the marketing is to convince the
customer of a better and easier experience in taking medication. The
major reason for developing new drug delivery methods for the
pharmaceutical industry is to extend the life-cycle of common and
familiar drugs.
The fast-dissolve tablet industry was historically dominated by the
creators of Zydis® and Lyoc®. Improvements in these technologies,
especially with taste masking, have emerged more recently with new
products by Biovail, Cima, Ethypharm, Eurand, and Yamanouchi. I’ve
grouped the research results by topic to help you with analyzing the
results.
I wish you well in your explorations of this industry.
czh
=================================================
FAST DISSOLVING TABLETS -- BACKGROUND INFORMATION
=================================================
http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=45
Articles: Life-Cycle Management: The Link to Drug Delivery
In the next 5 years, at least 18 blockbuster products with combined
sales of more than $37 billion will lose patent protection. By 2010,
an additional 300 drugs will go off patent. With increasing generic
competition and escalating NCE develop-ment expenses, drug companies
face growing pressure to maximize the value of their drugs throughout
their life cycles and improve the return on investment for their
product portfolio.
Biopharmaceutical companies look to the drug delivery industry for
technologies that can assist in their development and marketing
strategies for these products. Currently, the most sought after drug
delivery technologies include those that provide bioavailability
enhancement, quicker onset of action, fast-dissolve formulations,
parenteral solubili-zation, parenteral controlled-release systems,
needle-free injections, pulmonary delivery, improved transdermal
delivery, and novel vaccine delivery systems.
The drug delivery industry is responding as demonstrated by the number
of novel and validated technologies being introduced into the
marketplace. For example, historically, there were two widely used
fast-dissolve tablet technologies, Zydis® and Lyoc®. Both technologies
were based on freeze-drying processes and, while successful for use
with certain active ingredients, both technologies had some
limitations, including taste-masking and drug-loading capabilities.
Recent technological advances have resulted in new products by
Biovail, Cima, Ethypharm, Eurand, and Yamanouchi that provide
additional taste-masking and drug-loading capabilities.
Drug delivery is an extremely valuable life-cycle management tool. It
provides a number of strategic opportunities to both protect and
expand brand franchises through extended patent lives, new
indications, and novel dosage forms.
http://www.samedanltd.com/homepage/pmpsSample.htm
Uncontrolled Growth of Controlled Release
Drug Delivery Technology and Markets
http://otc.isu.edu/~das/Presentations-2001-pdf/Zydis.pdf
The Zydis Drug Delivery System
11 page report on rapid dissolve tablet process
http://www.pharmaquality.com/advanced.html
Advanced Drug Delivery: On Time and On Target
R.P. Scherer commercialized in 1986 a fast-melt tablet system, called
Zydis®, that dissolves in the mouth in seconds. "It dissolves in the
mouth and creates a liquid suspension. There's no lump to swallow and
you don't have to take it with water," Kearney says. The technology is
used in products such as Imodium, an antidiarrheal compound
manufactured by Janssen/ J&J; Pepcid, an antiulcer compound
manufactured by Merck & Co.; and Claritin, an antihistamine compound
manufactured by Schering Plough. It is also being investigated for use
in oral vaccines.
http://www.elan.com/DrugDelivery/technologies/fastmelt.asp
Fast-melt tablets have emerged as a patient-friendly, convenient
method of administering medications. Fast-melt technology is
particularly applicable to life cycle management opportunities to
allow additional formulation presentations of a successful drug.
Fast-melt technology has a perceived faster onset of action as the
dosage form is disintegrated prior to reaching the stomach and is
ideal for acute diseases and particularly applicable to manage
breakthrough symptoms.
Fast-melt formulations serve the large number of patients who are
unwilling or unable to swallow conventional dosage forms, including
both geriatric and pediatric patients, and those patients whose
swallowing is compromized as a clinical symptom of disease.
Fast-melt tablets are generally characterized by a hydrophilic matrix,
which allows prompt disintegration of tablets when in contact with
saliva. The prompt disintegration releases the active drug moiety
trapped in the matrix permitting the patient to swallow the product in
the form of a liquid, or a suspension in the case of non-soluble
components.
http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=60
Articles: Superporous Hydrogels for Pharmaceutical & Other
Applications
DEVELOPMENT OF FAST-DISSOLVING TABLETS
http://atlas.pharmalicensing.com/licensing/browse/321
licensing Sector Drug delivery Oral solid Tablet
http://www.usanahealthsciences.com/research/Excip.shtml
Tablet Excipients
Excipients are inactive, non-medicinal ingredients that are used by
all manufacturers of tableted products to impart desirable
characteristics important for manufacture, convenience of use, and
product efficacy. Most are powdered materials that are blended with
the active ingredients prior to tableting.
http://www.pformulate.com/disintegrs.htm
Excipients
WHAT IS A DISINTEGRANT?
Some superdisintegrants and their properties are listed below.
http://www.glycologic.co.uk/tech.htm
The rapid disintegration tablet excipient (RDE) offers extremely fast
dissolution from tablets with good hardness made with standard
techniques. The excipient is made from inexpensive materials with low
toxicity using a straightforward process.
================================
FAST DISSOLVING TABLET COMPANIES
================================
http://www.spipharma.com/aboutus.html
SPI Pharma is a world wide leader in custom formulation solutions for
pharmaceutical and neutriceutical manufacturers. By offering raw
materials, processing capabilities, and advanced application
technologies we have become a valued source for complete custom
delivery systems. This provides a competitive advantage for our
customers’ formulations.
Pharmaburst is SPI Pharma’s new easy to use “quick dissolve” tablet
delivery platform.
http://www.eurand.com/page.php?sid=3
Eurand is a specialty pharmaceutical company that develops enhanced
pharmaceutical and biopharmaceutical products using our innovative
drug delivery technologies. The Company’s drug development efforts are
based on three commercialized technology platforms; bioavailability
enhancement of poorly soluble drugs, customized release and taste
masked/quick dissolving formulations. Eurand has recently added a
fourth technology platform, drug targeting, to its capabilities that,
once commercialized, can be applied to small molecule and
biotechnology derived products for improved drug delivery.
http://www.kinam.com/
Akina, Inc.
Designing the Future Drug Delivery Technologies.
Engineering and research services specializing in controlled drug
delivery and design of biomedical products.
http://www.antarespharma.com/content/products/melting/
The combined technologies of needle-free, mini-needle and transdermal
gel position Antares Pharma to become a leader in drug delivery
systems – a market that is large, global and growing.
Many patients have difficulty swallowing tablets and hard gelatine
capsules, and consequently do not take medications as prescribed. It
is estimated that 50% of the population is affected by this problem,
which results in a high incidence of non-compliance and ineffective
therapy.
http://atlas.pharmalicensing.com/company/disprelease/1024926104_3d17219864311
ETHYPHARM AND VIATRIS TO MAKE TREATMENT OF MODERATE TO SEVERE PAIN
MORE CONVENIENT
Ethypharm, one of the world's leading drug delivery system (DDS)
companies, and VIATRIS (formerly ASTA Medica), announce today that
they have entered into a collaboration to develop an innovative oral
formulation of Tramadol for the relief of moderate to severe pain,
using Ethypharm´s unique Flashtab® technologies.
http://www.ethypharm.com/generate.htm?1
Ethypharm is one of the world's leading drug delivery systems (DDS)
companies that provides a range of effective solutions to optimise the
delivery of pharmaceutical products
http://atlas.pharmalicensing.com/company/dc/459#profile
Ethypharm
Innovative Drug Delivery Solutions provider (full profile)
Many news articles about technologies and capabilities
http://www.kvpharmaceutical.com/tech/3_quick_dissolving_tablets.html
The system under development at KV allows for the ability to
tastemask, while at the same time dissolve a wide range of drug
candidates quickly in the mouth.
http://www.taisho.co.jp/outline/rls/htm/101900-e.htm
Product Release: Semper QT, Quick Dissolving Motion Sickness Tablets
http://www.ther-rx.com/news/1_company_fact_sheet.asp
Wholly owned subsidiary of KV Pharmaceutical Company (KV), the Ther-Rx
Corporation uses advanced, patented drug-delivery technologies to
create unique and revolutionary prescription products.
Through our innovative and unique technologies, such as SITE RELEASE®,
tastemasking, quick-dissolving tablets, and oral extended/delayed
release, we're working to advance medicine in order to improve our
patients' health and well-being.
http://www.pslgroup.com/dg/16d5ce.htm
Benadryl Allergy/Cold Fastmelt Tablets Now Available In The US
PALO ALTO, CA --February 23, 2000 -- Yamanouchi Pharma Technologies,
Inc. and Warner-Lambert Company announced the national launch of
Benadryl(R) Allergy/Cold Fastmelt(R) tablets. This product represents
the first launch of the WOWTAB(R) quick-dissolve dosage form in North
America, and the first product to emerge from an exclusive
development, license and supply partnership between the companies
involving the market-leading Benadryl franchise.
http://www.spipharma.com/ProductsFolder/127PharmaBurst/127PharmaBurst-TB.pdf
PharmaBurst “Quick Dissolve” Delivery System for Tablets
http://www.cardinal.com/content/news/062300_100566.asp
R.P. Scherer to Acquire Rights to Proprietary Topical Delivery
Technologies from Advanced Polymer Systems
BASKING RIDGE, N.J., June 23 /PRNewswire/ - R.P. Scherer Corporation,
a subsidiary of Cardinal Health, Inc. (NYSE: CAH) and a leading
developer and manufacturer of soft- gelatin capsules, rapid-dissolving
tablets and other drug delivery systems, announced today it has agreed
to acquire a manufacturing center and the rights to two proprietary,
topical drug delivery technologies from Advanced Polymer Systems, Inc.
of Redwood City, California.
http://www.cimalabs.com/tech.htm
CIMA LABS INC. (Nasdaq: CIMA) develops and manufactures prescription
and over-the-counter products based upon its proprietary,
fast-dissolve drug delivery technologies, OraSolv® and DuraSolv®.
The fast dissolve technologies are: OraSolv®, Sustained
Release/Controlled Release and DuraSolv®.
We develop and manufacture drugs for pharmaceutical company partners.
At year-end 2001, CIMA was manufacturing three branded prescription
pharmaceuticals (for AstraZeneca, Organon and Schwarz Pharma) and two
over-the counter brands (for Novartis and Mead Johnson, an affiliate
of Bristol-Myers Squibb).
http://www.hoovers.com/co/capsule/2/0,2163,42142,00.html
CIMA LABS makes pills that melt in your mouth. Through its OraSolv
technology, CIMA makes coatings that microencapsulate drugs -- mostly
prescription products -- into tablets that dissolve quickly in the
mouth for ingestion without water or chewing.
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=CEPH&script=1801
Cephalon -- Business Strategy, Product Sales & Future Outlook
Cephalon’s international presence grew dramatically in 2001, and the
acquisition of products and companies continues to be part of the
company’s growth strategy. In 2001, Cephalon acquired additional
rights to GABITRIL and completed the acquisition of Laboratoire L.
Lafon, a major pharmaceutical company in France. Each of these
acquisitions is expected to be rapidly accretive to earnings at
Cephalon and serve not only to broaden our product portfolio but also
our global reach.
Lafon’s “Lyoc” delivery technology, which is used to create
rapid-dissolve tablets, complements Cephalon's oral transmucosal
technology being developed in our Salt Lake City facility.
===============
SEARCH STRATEGY
===============
fast melting tablets
rapid disintegration tablet
rapid dissolve technology
"rapid dissolve" "drug delivery" |
,
0 Comments
)